UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co. (NYSE: LLY) to discover novel therapeutic candidates for the treatment of amyotrophic lateral sclerosis (ALS). This alliance is designed to accelerate the development of up to five new therapies for this debilitating condition.
Agreement Details
Under the terms of the agreement, Alchemab will receive an undisclosed upfront payment and is eligible to receive discovery, development, and commercialization milestone payments, plus royalties. The collaboration involves the discovery, development, and commercialization of up to five novel therapies, leveraging Alchemab’s innovative technology and Eli Lilly’s expertise in drug development.
Alchemab’s Technology and Goals
Alchemab has acquired hundreds of ALS samples and expects to identify antibodies associated with resilience in ALS patient samples using its proprietary technology. The company aims to advance the most promising candidates through the development pipeline, potentially offering new hope for patients suffering from ALS.
Significance of the Partnership
This partnership between Alchemab Therapeutics and Eli Lilly & Co. highlights the commitment of both companies to advancing innovative treatments for ALS. By combining Alchemab’s cutting-edge technology with Eli Lilly’s resources and experience, the collaboration aims to bring novel therapies to market, improving patient outcomes and quality of life.-Fineline Info & Tech
